Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes

British Journal of Cancer

Volumn 110, Issue 1, 2014, Pages 123-132

  Teng, P N ^a   Wang, G ^a   Hood, B L ^a   Conrads, K A ^a   Hamilton, C A ^a,b   Maxwell, G L ^a,c   Darcy, K M ^a   Conrads, T P ^a  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

biomarker; cisplatin resistance; ovarian cancer; proteomics; secretome

Indexed keywords

CISPLATIN; COLLAGEN TYPE 11; COLLAGEN TYPE 11 A1; MEMBRANE PROTEIN; SECRETOME; TRYPSIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; OVARY CARCINOMA; OVERALL SURVIVAL; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

CELL LINE, TUMOR; CISPLATIN; COLLAGEN TYPE XI; CULTURE MEDIA; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTEOMICS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891881554     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.687     Document Type: Article

References (46)

1. Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S, Kuliopulos A (2008) Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 7: 2746-2757.
2. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 3: 235-244. (Pubitemid 38500990)
3. Ansell A, Jerhammar F, Ceder R, Grafstrom R, Grenman R, Roberg K (2009) Matrix metalloproteinase-7 and-13 expression associate to cisplatin resistance in head and neck cancer cell lines. Oral Oncol 45: 866-871.
4. Bauvois B (2012) New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36.
5. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 68: 5478-5486.
6. Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, Gromova I (2005) Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 4: 492-522. (Pubitemid 40590568)
7. Chen Y, Zhang Y, Yin Y, Gao G, Li S, Jiang Y, Gu X, LUO J (2005) SPD-a web-based secreted protein database. Nucleic Acids Res 33: D169-D173. (Pubitemid 40207853)
8. Coticchia CM, Curatolo AS, Zurakowski D, Yang J, Daniels KE, Matulonis UA, Moses MA (2011) Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol 123: 295-300.
9. Denkert C, Budczies J, Darb-Esfahani S, Gyorffy B, Sehouli J, Konsgen D, Zeillinger R, Weichert W, Noske A, Buckendahl AC, Muller BM, Dietel M, Lage H (2009) A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J Pathol 218: 273-280.
10. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525. (Pubitemid 350002958)
11. Faca VM, Ventura AP, Fitzgibbon MP, Pereira-Faca SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'briant KC, Drescher CW, Schummer M, Mcintosh MW, Knudsen BS, Hanash SM (2008) Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 3: e2425.
12. Farrah T, Deutsch EW, Omenn GS, Campbell DS, Sun Z, Bletz JA, Mallick P, Katz JE, Malmstrom J, Ossola R, Watts JD, Lin B, Zhang H, Moritz RL, Aebersold R (2011) A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics 10: M110 006353.
13. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, KeO, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883.
14. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, Huttenhower C, Waldron L (2013) CuratedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database 2013: bat013.
15. Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, Onge ST, Kireeva P, Schmitt-Ulms I, Brown G, Murphy TJ, Rosen J, Shaw B, Jurisica P, Kislinger, T. I (2008) A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res 7: 339-351. (Pubitemid 351171148)
16. Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP (2009) Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. J Proteome Res 8: 4705-4713.
17. Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579. (Pubitemid 351483371)
18. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U (2006) Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95(Suppl 1): S161-S192.
19. Hoskins ER, Hood BL, Sun M, Krivak TC, Edwards RP, Conrads TP (2011) Proteomic analysis of ovarian cancer proximal fluids: validation of elevated peroxiredoxin 1 in patient peripheral circulation. PLoS One 6: e25056.
20. Justilien V, Regala RP, Tseng IC, Walsh MP, Batra J, Radisky ES, Murray NR, Fields AP (2012) Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation and metastatic potential. PLoS One 7: e35040.
21. Kim H, Watkinson J, Varadan V, Anastassiou D (2010) Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics 3: 51.
22. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP (2009) Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 8: 661-669.
23. Liu J, Guo S, LI Q, Yang L, Xia Z, Zhang L, Huang Z, Zhang N (2013) Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J Neurooncol 111: 245-255.
24. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874.
25. Marengo E, ROBOTTI E, Bobba M, Gosetti F (2010) The principle of exhaustiveness vs the principle of parsimony: a new approach for the identification of biomarkers from proteomic spot volume datasets based on principal component analysis. Anal Bioanal Chem 397: 25-41.
26. Mcdonald JH (2009) Handbook of Biological Statistics. Sparky House Publishing: Baltimore, MD, USA 160-164.
27. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16: 521-532.
28. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119: 1338-1344. (Pubitemid 44258809)
29. Regala RP, Justilien V, Walsh MP, Weems C, Khoor A, Murray NR, Fields AP (2011) Matrix metalloproteinase-10 promotes Kras-mediated bronchioalveolar stem cell expansion and lung cancer formation. PLoS One 6: e26439.
30. Rosado JO, Salvador M, Bonatto D (2007) Importance of the transsulfuration pathway in cancer prevention and promotion. Mol Cell Biochem 301: 1-12. (Pubitemid 46895141)
31. Sedlaczek P, Frydecka I, Gabrys M, VAN Dalen A, Einarsson R, Harlozinska A (2002) Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 95: 1886-1893. (Pubitemid 35222168)
32. Seliger B, Handke D, Schabel E, Bukur J, Lichtenfels R, Dammann R (2009) Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med 7: 90.
33. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
34. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
35. Solar P, Sytkowski AJ (2011) Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett 309: 11-18.
36. Sole S, Petegnief V, Gorina R, Chamorro A, Planas AM (2004) Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol 63: 338-349. (Pubitemid 38429031)
37. Stott-Miller M, Houck JR, Lohavanichbutr P, Mendez E, Upton MP, Futran ND, Schwartz SM, Chen C (2011) Tumor and salivary matrix metalloproteinase levels are strong diagnostic markers of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 20: 2628-2636.
38. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP (2011) Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid. J Proteome Res 10: 1333-1342.
39. Teng PN, Rungruang BJ, Hood BL, Sun M, Flint MS, Bateman NW, Dhir R, Bhargava R, Richard SD, Edwards RP, Conrads TP (2010) Assessment of buffer systems for harvesting proteins from tissue interstitial fluid for proteomic analysis. J Proteome Res 9: 4161-4169.
40. Tesshi Yamada KH, Wilber Huang (2012) Use of overexpression of cystathionine gamma lysase as a prognostic, diagnostic and therapeutic target for cancer. Japan, Taiwan patent application 20120058204.
41. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
42. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, Defazio A, Bowtell DD (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
43. Wen J, Zheng B, Hu Y, Zhang X, Yang H, LI Y, Zhang CY, Luo KJ, Zang X, Li YF, Guan XY, Fu JH (2010) Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol 36: 265-274.
44. Xiang T, Li L, Yin X, Yuan C, Tan C, SU X, Xiong L, Putti TC, Oberst M, Kelly K, Ren G, Tao Q (2012) The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One 7: e29783.
45. Yin P, Zhao C, Li Z, Mei C, Yao W, Liu Y, Li N, Qi J, Wang L, Shi Y, Qiu S, Fan J, Zha X (2012) Sp1 is involved in regulation of cystathionine gamma-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. Cell Signal 24: 1229-1240.
46. Yu J, Tao Q, Cheung KF, Jin H, Poon FF, Wang X, Li H, Cheng YY, Rocken C, Ebert MP, Chan AT, Sung JJ (2008) Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology 48: 508-518.